According to recent studies, the serum concentration of GM3 is higher in patients with type 2 diabetes, hyperlipidemia, and obese patients, while GM3 can promote the removal of insulin receptors and reduce insulin signaling 19. This evidence concerns the gene INS and hyperlipidemia.